Business
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiencyGENFIT remains listed on the regulated market of Euronext Paris as its primary trading market Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced it
About this update from Genfit Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiency","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"GENFIT remains listed on the regulated market of Euronext Paris as its primary trading market","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":225,"olType":false},{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced it has given formal notice to the Nasdaq Stock Market of the Company’s intention to voluntarily delist its American Depositary Shares (“ADSs”) representing its ordinary shares. Delisting is anticipated to be effective prior to the opening of trading on November 20, 2025, at which time the ADSs will no longer trade on the Nasdaq Global Select Market.","length":623,"tagName":"p"},{"type":"text","content":"Ordinary shares of GENFIT have been listed on the regulated market of Euronext Paris since April 2014. The Company listed the ADSs on the Nasdaq Global Select Market in March 2019. The ADSs trade in U.S. dollars.","length":212,"tagName":"p"},{"type":"text","content":"Pascal Prigent, CEO of GENFIT, commented: “With a strong financial foundation underpinned by the successful development and commercialization of elafibranor in PBC, the decision to delist from Nasdaq is an opportunity to streamline operations and focus resources. This move supports greater operational efficiency and is consistent with our current pipeline development stage. We remain fully committed to our Euronext listing and to upholding high standards of corporate governance and transparency."","length":506,"tagName":"p"},{"type":"text","content":"GENFIT remains listed on Euronext Paris as its primary trading market and intends to continue its disclosures in compliance with applicable French and European financial market regulations. GENFIT intends to file a Form 25 to initiate the removal of the ADS listing from the Nasdaq Global Select Market, which will be effective ten days after the filing of the Form 25. Thereafter, GENFIT intends to file a Form 15F ...